Ipertermia radiototerapia e chemioterapia nuovi sviluppi

Questo articolo tratta di una review circa la bontà dell'approccio in ipertermia oncologica.

Traducendo l'ultima frase: “Questi recenti sviluppi, supportati da evidenze cliniche positive, consentono di stabilire che l'ipertermia dovrebbe essere aggiunta all'armamentario terapeutico in qualità di efficace e sicuro (dal punto di vista degli effetti collaterali) potenziamento rispetto alle modalità terapeutiche classiche”

Dr. Carlo Pastore

Cancer Treat Rev. 2015 Nov;41(9):742-53. doi: 10.1016/j.ctrv.2015.05.009. Epub 2015 May 27.

Local hyperthermia combined with radiotherapy and-/or chemotherapy: recent advances and promises for the future.

Datta NR1, Ordóñez SG2, Gaipl US3, Paulides MM4, Crezee H5, Gellermann J6, Marder D7, Puric E8, Bodis S9.

Author information

Abstract

Hyperthermia, one of the oldest forms of cancer treatment involves selective heating of tumor tissues to temperatures ranging between 39 and 45°C. Recent developments based on the thermoradiobiological rationale of hyperthermia indicate it to be a potent radio- and chemosensitizer. This has been further corroborated through positive clinical outcomes in various tumor sites using thermoradiotherapy or thermoradiochemotherapy approaches. Moreover, being devoid of any additional significant toxicity, hyperthermia has been safely used with low or moderate doses of reirradiation for retreatment of previously treated and recurrent tumors, resulting in significant tumor regression. Recent in vitro and in vivo studies also indicate a unique immunomodulating prospect of hyperthermia, especially when combined with radiotherapy. In addition, the technological advances over the last decade both in hardware and software have led to potent and even safer loco-regionalhyperthermia treatment delivery, thermal treatment planning, thermal dose monitoring through noninvasive thermometry and online adaptive temperature modulation. The review summarizes the outcomes from various clinical studies (both randomized and nonrandomized) wherehyperthermia is used as a thermal sensitizer of radiotherapy and-/or chemotherapy in various solid tumors and presents an overview of the progresses in loco-regional hyperthermia. These recent developments, supported by positive clinical outcomes should merit hyperthermia to be incorporated in the therapeutic armamentarium as a safe and an effective addendum to the existing oncological treatment modalities.